Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry-Reference-Cited by-同舟云学术

Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Published:2022-03-30 Issue:7 Volume:41 Page:2053-2063
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Bodur Hatice^ORCID,Yurdakul Fatma Gul^ORCID,Ataman Sebnem^ORCID,Cay Hasan Fatih^ORCID,Gurer Gulcan^ORCID,Capkin Erhan^ORCID,Sezer İlhan^ORCID,Duruoz Mehmet Tuncay^ORCID,Melikoglu Meltem Alkan^ORCID,Rezvani Aylin^ORCID,Yagci Ilker^ORCID,Gogus Feride^ORCID,Kamanli Ayhan^ORCID,Akgul Ozgur^ORCID,Cevik Remzi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-022-06145-8.pdf

Reference34 articles.

1. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D (2019) A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71:1101-1111.: https://doi.org/10.1002/art.40866

2. Rodrigues-Manica S, Silva J, Cruz-Machado R, Coelho C, Duarte J, Vieira-Sousa E, Tavares-Costa J, Pimentel-Santos FM (2021) Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. Clin Rheumatol 40:33–41. https://doi.org/10.1007/s10067-020-05209-x

3. Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A (2019) Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 7;5:e000917.: https://doi.org/10.1136/rmdopen-2019-000917

4. Shimabuco AY, Gonçalves CR, Moraes JCB, Waisberg MG, Ribeiro ACM, Sampaio-Barros PD, Goldenstein-Schainberg C, Bonfa E, Saad CGS (2018) Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Adv Rheumatol. 4;58:40.: https://doi.org/10.1186/s42358-018-0040-x

5. Chen X, Zhang T, Wang W, Xue J (2018) Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin Rheumatol 37:1625–1632. https://doi.org/10.1007/s10067-018-4084-4

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry;Rheumatology International;2024-02-06

2. Cardiovascular comorbidities in spondyloarthritis;Clinical Rheumatology;2022-12-13